Ata uhi

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency

<p>Abstract</p> <p>Background</p> <p>Substitution with opioid-agonists (e.g., methadone) has shown to be an effective treatment for chronic long-term opioid dependency. Patient satisfaction with treatment has been associated with improved addiction treatment outcomes. H...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Brissette Suzanne (Author), Guh Daphne (Author), Oviedo-Joekes Eugenia (Author), Marchand Kirsten I (Author), Marsh David C (Author), Schechter Martin T (Author)
Hōputu:	Pukapuka
I whakaputaina:	BMC, 2011-07-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
mā: Marchand Kirsten, me ētahi atu.
I whakaputaina: (2012)

Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder
mā: Heather Palis, me ētahi atu.
I whakaputaina: (2017)

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
mā: Scott Beaumont, me ētahi atu.
I whakaputaina: (2024)

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
mā: Kirsten Marchand, me ētahi atu.
I whakaputaina: (2020)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
mā: Dobischok S, me ētahi atu.
I whakaputaina: (2023)

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment
mā: Heather Palis, me ētahi atu.
I whakaputaina: (2021)

Feasibility of Applying the Life History Calendar in a Population of Chronic Opioid Users to Identify Patterns of Drug Use and Addiction Treatment
mā: Jill Fikowski, me ētahi atu.
I whakaputaina: (2014)

Feasibility of Applying the Life History Calendar in a Population of Chronic Opioid Users to Identify Patterns of Drug Use and Addiction Treatment
mā: Jill Fikowski, me ētahi atu.
I whakaputaina: (2014)

Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
mā: Eugenia Oviedo-Joekes, me ētahi atu.
I whakaputaina: (2023)

Risk factors for poor treatment outcomes among opioid-dependent clients taking methadone in Mombasa, Kenya
mā: Nassoro Mwanyalu, me ētahi atu.
I whakaputaina: (2024)

Higher methadone dose reduces risky drug injecting behaviours among methadone clients in Myanmar
mā: Sun Tun, me ētahi atu.
I whakaputaina: (2021)

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
mā: Eugenia Oviedo-Joekes, me ētahi atu.
I whakaputaina: (2021)

Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK
mā: Byford Sarah, me ētahi atu.
I whakaputaina: (2006)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
mā: Alison Adams, me ētahi atu.
I whakaputaina: (2023)

Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review
mā: Kirsten Marchand, me ētahi atu.
I whakaputaina: (2019)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
mā: Heather Palis, me ētahi atu.
I whakaputaina: (2021)

Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment
mā: Maximilian Meyer, me ētahi atu.
I whakaputaina: (2022)

Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes
mā: Lund IO, me ētahi atu.
I whakaputaina: (2012)

Gender disparities in opioid treatment progress in methadone versus counseling
mā: Erick Guerrero, me ētahi atu.
I whakaputaina: (2021)

Client satisfaction to methadone maintenance treatment program in Myanmar
mā: Sun Tun, me ētahi atu.
I whakaputaina: (2022)

"As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises
mā: Kaitlyn Jaffe, me ētahi atu.
I whakaputaina: (2023)

Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China
mā: Yan Zhao, me ētahi atu.

Effectiveness of Relapse Prevention Cognitive Behavioral Model in Opioid Dependent Patients Participating in the Methadone Maintenance Treatment in Iran
mā: Fatemeh Rajati, me ētahi atu.
I whakaputaina: (2013)

Effectiveness of Relapse Prevention Cognitive-Behavioral Model in Opioid-Dependent Patients Participating in the Methadone Maintenance Treatment in Iran.
mā: Tahereh Pashaei, me ētahi atu.
I whakaputaina: (2013)

Comparison of Pain Tolerance between Opioid Dependent Patients on Methadone Maintenance Therapy (MMT) and Opioid Naive Individuals
mā: Zalina Zahari, me ētahi atu.
I whakaputaina: (2016)

Correction to: Client satisfaction to methadone maintenance treatment program in Myanmar
mā: Sun Tun, me ētahi atu.
I whakaputaina: (2022)

A Preliminary Study of Sexual Dysfunction in Male Opioid-Dependants under Methadone Maintenance Treatment
mā: Masoudeh Babakhanian, me ētahi atu.
I whakaputaina: (2011)

Persistence in the Methadone Maintenance Program and Its Relationship with the Medication Regimen Complexity Index in Opioid-Dependent Patients
mā: Elena Alba Álvaro-Alonso, me ētahi atu.
I whakaputaina: (2024)

NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America
mā: Laliberté Nancy, me ētahi atu.
I whakaputaina: (2009)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
mā: Ingunn O. Lund, me ētahi atu.
I whakaputaina: (2013)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
mā: Ingunn O. Lund, me ētahi atu.
I whakaputaina: (2013)

Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care
mā: Cinzia Baschirotto, me ētahi atu.
I whakaputaina: (2020)

Assessing the spatial distribution of methadone clinic clients and their access to treatment
mā: Wong Ngai, me ētahi atu.
I whakaputaina: (2010)

Comment on "A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes"
mā: Robert G. Newman M.D., M.P.H, me ētahi atu.
I whakaputaina: (2013)

Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals
mā: Rapeli Pekka, me ētahi atu.
I whakaputaina: (2009)

Comment on "A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes"
mā: Robert G. Newman, me ētahi atu.
I whakaputaina: (2013)

Long-Acting Injectable Naltrexone for the Management of Patients with Opioid Dependence
mā: Kimberly L. Kjome, me ētahi atu.
I whakaputaina: (2011)

Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence
mā: Kimberly L. Kjome, me ētahi atu.
I whakaputaina: (2011)

Better retention of Malaysian opiate dependents treated with high dose methadone in methadone maintenance therapy
mā: Talib Nazila, me ētahi atu.
I whakaputaina: (2010)

Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities
mā: Björn Johnson, me ētahi atu.
I whakaputaina: (2019)